Loss of facial nerve function after a facial nerve injury is a devastating injury that has profound cosmetic, functional, and psychological implications. The current management of long-term facial nerve injury relies on the inherent regenerative capabilities of the facial nerve supported by static and active surgical procedures to improve both function and cosmesis. A compound currently used for immunosuppression, FK506, has been identified as a potential neuroprotectant and neuroregenerator. Corey Yeh, MD, and colleagues have performed a randomized controlled trial to study the neuromodulating effects of FK506 in rat facial nerves by measuring the rat blink reflex return, vibrissial fibrillation loss, and return of vibrissial sweeping symmetry after facial nerve injury. To further characterize the recovery mechanism, recovery rate was also examined in animals receiving a monoclonal antibody to a known FK506 receptor, FK binding protein 52. They determined that this compound does improve facial nerve function recovery in the rat facial nerve model.